Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary. We designed a clinical trial to investigate two hypotheses: i) higher doses of venetoclax ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutman, Jonathan A., Winters, Amanda, Kent, Andrew, Amaya, Maria, McMahon, Christine, Smith, Clayton, Jordan, Craig T., Stevens, Brett, Minhajuddin, Mohammad, Pei, Shanshan, Schowinsky, Jeffrey, Tobin, Jennifer, O’Brien, Kelly, Falco, Angela, Taylor, Elizabeth, Brecl, Constance, Zhou, Katie, Ho, Phuong, Sohalski, Connor, Dell-Martin, Jessica, Ondracek, Olivia, Abbott, Diana, Pollyea, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Acute Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542846/
https://www.ncbi.nlm.nih.gov/pubmed/37051756
http://dx.doi.org/10.3324/haematol.2023.282681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542846/
https://www.ncbi.nlm.nih.gov/pubmed/37051756
http://dx.doi.org/10.3324/haematol.2023.282681

Ejemplares similares